The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

At the 2-year, 3-year, and 4-year time points from the index date, those taking semaglutide had an increased risk for nonarteritic anterior ischemic optic neuropathy. HealthDay News — For patients ...

Despite its benefits, semaglutide may be linked to nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition. Current research does not establish causality between semaglutide ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...